期刊文献+
共找到10篇文章
< 1 >
每页显示 20 50 100
乙肝病毒与肝细胞癌发生的诱变关系 被引量:2
1
作者 戴益民 《世界华人消化杂志》 CAS 1998年第S2期45-49,共5页
关键词 乙型炎病毒 肿瘤/病因 癌.肝细胞/病因学
下载PDF
丙型肝炎病毒患者抗病毒干预持续应答后发生肝细胞肝癌的临床特征 被引量:2
2
作者 刘冬宇 白劼 +1 位作者 张文华 郝艳霞 《医学临床研究》 CAS 2021年第3期356-358,361,共4页
【目的】研究丙型肝炎病毒(HCV)直接抗病毒药物(DAA)抗病毒干预获得持续病毒学应答(SVR)后发生肝细胞肝癌(HCC)患者的临床特征。【方法】纳入本院130例HCV感染患者作为研究对象,所有患者均接受HCV抗病毒治疗,记录SVR情况。出院后随访记... 【目的】研究丙型肝炎病毒(HCV)直接抗病毒药物(DAA)抗病毒干预获得持续病毒学应答(SVR)后发生肝细胞肝癌(HCC)患者的临床特征。【方法】纳入本院130例HCV感染患者作为研究对象,所有患者均接受HCV抗病毒治疗,记录SVR情况。出院后随访记录HCC发生率。根据是否发生HCC,将获得SVR的患者分为观察组(发生HCC)和对照组(未发生HCC)。比较两组患者基本资料和临床病理特点,采用Cox多因素风险模型探讨经HCV抗病毒干预后获得SVR患者发生HCC的高危因素。【结果】130例患者中98例达到SVR效果,SVR率为75.38%,在98例患者中,随访期间共发生HCC6例,发生率6.12%。不同预后患者DAA治疗情况、肝脏状态、谷草转氨酶(AST)、谷丙转氨酶(ALT)及甲胎蛋白(AFP)水平比较差异均有显著性(P<0.05)。Cox多因素风险分析显示ADD治疗情况、肝脏状态及AFP水平是HCV抗病毒治疗获得SVR的患者后发生HCC的危险因素(均P<0.05)。【结论】对于HCV抗病毒干预治疗后达到SVR的患者,患者DAA治疗情况、肝脏状态及AFP水平是影响患者发生HCC的独立因素。 展开更多
关键词 丙型炎/治疗 抗病毒药 肝细胞/病因学 预后
下载PDF
原发性肝癌伴门静脉癌栓临床分析 被引量:2
3
作者 俞婷 孙为豪 +3 位作者 李嘉 俞谦 曹大中 欧希龙 《陕西医学杂志》 CAS 北大核心 2005年第11期1353-1355,共3页
目的:探讨原发性肝癌(肝癌)患者门静脉癌栓(PVTT)形成的相关因素和临床特点。方法:回顾性分析肝癌106例,彩色多普勒超声检查PVTT,总结PVTT与肝癌患者年龄、肝硬化基础、肝硬化严重程度、血清乙型肝炎表面抗原(HBsAg)、丙氨酸氨基转移酶(... 目的:探讨原发性肝癌(肝癌)患者门静脉癌栓(PVTT)形成的相关因素和临床特点。方法:回顾性分析肝癌106例,彩色多普勒超声检查PVTT,总结PVTT与肝癌患者年龄、肝硬化基础、肝硬化严重程度、血清乙型肝炎表面抗原(HBsAg)、丙氨酸氨基转移酶(ALT)和肿瘤指标(AFP和CEA)的相关性。门静脉高压症的诊断依据门静脉直径大于13mm,或胃镜显示食管-胃底静脉曲张。结果:106例肝癌中合并PVTT28例,其中年龄在40岁以下者占42.9%。有肝硬化基础或HBsAg阳性病例的PVTT发生率显著高于无肝硬化基础或HBsAg阴性病例,肝硬化为ChildB级和ChildC级的PVTT发生率显著高于ChildA级病例。而ALT、AFP和CEA与PVTT的发生率无明显相关性。肝癌伴有PVTT的门静脉高压症发生率显著高于无PVTT者。结论:年轻人、伴有肝硬化基础、和HBsAg阳性的肝癌,PVTT发生率高,肝硬化越重的PHC,越容易形成PVTT。PVTT形成后门静脉高压症的发生率增加。 展开更多
关键词 肿瘤/并发症 肿瘤循环细胞静脉闭塞性疾病/病因 静脉闭塞性疾病/诊断 原发性 门静脉癌栓 乙型炎表面抗原(HBsAg) 丙氨酸氨基转移酶(ALT) 临床分析 彩色多普勒超声检查 门静脉高压症
下载PDF
Caveolin-1在肝细胞癌表达及与肿瘤血管生成的关系 被引量:10
4
作者 张志波 何庆良 +1 位作者 石铮 董家鸿 《中国普通外科杂志》 CAS CSCD 北大核心 2012年第1期53-57,共5页
目的:探讨caveolin-1与肝细胞癌(HCC)侵袭转移的关系及其可能的机制。方法:应用实时PCR方法检测伴肝内转移的HCC组织、癌旁组织、肝硬化组织、正常肝组织中caveolin-1 mRNA的表达;用Western blot方法检测伴肝内转移的HCC组织、癌旁组织... 目的:探讨caveolin-1与肝细胞癌(HCC)侵袭转移的关系及其可能的机制。方法:应用实时PCR方法检测伴肝内转移的HCC组织、癌旁组织、肝硬化组织、正常肝组织中caveolin-1 mRNA的表达;用Western blot方法检测伴肝内转移的HCC组织、癌旁组织中caveolin-1蛋白的表达;用免疫组化方法检测75例HCC组织中caveolin-1,血管内皮生长因子(VEGF),CD34,α-平滑肌肌动蛋白(α-SMA)的表达,分析caveolin-1,VEGF的表达以及肿瘤微血管密度(MVD),非成对动脉(UA)计数与临床病理因素的关系。结果:在伴肝内转移的HCC组织中,caveolin-1 mRNA表达明显高于癌旁组织、肝硬化组织、正常肝组织(均P<0.05),其蛋白表达明显高于癌旁组织;caveolin-1表达水平的升高与肿瘤转移有关(P<0.05),且caveolin-1的表达与VEGF表达及MVD和UA计数呈正相关(r=0.293,P=0.011;r=0.361,P=0.001;r=0.388,P=0.001)。结论:caveolin-1表达升高促进HCC的侵袭转移,其机制可能是通过诱导HCC表达VEGF,促进肿瘤新生血管生成而实现的。 展开更多
关键词 肝细胞/病因学 窖蛋白-1 肿瘤转移 血管生成 病理性
原文传递
影响TACE治疗乙型肝炎相关性肝细胞癌患者预后的相关因素分析 被引量:4
5
作者 陈思珊 叶雪卫 《中国医师杂志》 CAS 2018年第4期568-570,共3页
目的探讨影响肝动脉化疗栓塞(TACE)治疗乙型肝炎相关性肝细胞癌患者预后的相关因素。方法随机选取2013年1月至2015年12月本院收治的已于上级医院行TACE治疗的乙型肝炎相关性肝细胞癌患者120例作为研究对象,观察入选患者1年的生存情况,2... 目的探讨影响肝动脉化疗栓塞(TACE)治疗乙型肝炎相关性肝细胞癌患者预后的相关因素。方法随机选取2013年1月至2015年12月本院收治的已于上级医院行TACE治疗的乙型肝炎相关性肝细胞癌患者120例作为研究对象,观察入选患者1年的生存情况,2016年12月截止随访观察。多因素及单因素分析采用对数秩Log Rank(Mantel-cox)检验以及Kaplan Meier时序检验进行,对影响TACE治疗乙型肝炎相关性肝细胞癌患者的预后相关因素进行筛选分析。结果单因素分析结果表明抗病毒治疗、AST、血清胆红素、Child-Pugh分级、腹腔转移、胸腔转移、门静脉转移、年龄因素对患者预后有影响,在进行TACE治疗的同时联用抗病毒治疗较不联用抗病毒治疗方案的Child-Pugh A级患者生存期长,差异有统计学意义(P<0.05)。多因素分析结果显示TACE治疗次数(P<0.01)、抗病毒治疗(P<0.01)、胆红素水平(P=0.017)、腹腔转移(P=0.009)、门静脉转移(P=0.004)与TACE治疗的乙型肝炎相关性肝癌患者的预后相关。结论影响TACE治疗的乙型肝炎相关性肝细胞癌患者的预后独立危险因素可能包括胆红素水平、腹腔转移以及门静脉转移,而其相关保护性因素则可能包括TACE介入治疗的次数以及同时联合抗病毒治疗。 展开更多
关键词 乙型/并发症 肝细胞/病因学/治疗 栓塞 治疗性 预后
原文传递
Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis 被引量:80
6
作者 Asmaa Ibrahim Gomaa Shahid A Khan +2 位作者 Mireille B Toledano Imam Waked Simon D Taylor- Robinson 《World Journal of Gastroenterology》 SCIE CAS CSCD 2008年第27期4300-4308,共9页
Hepatocellular carcinoma (HCC) is the commonest primary malignant cancer of the liver in the world. Given that the burden of chronic liver disease is expected to rise owing to increasing rates of alcoholism, hepatitis... Hepatocellular carcinoma (HCC) is the commonest primary malignant cancer of the liver in the world. Given that the burden of chronic liver disease is expected to rise owing to increasing rates of alcoholism, hepatitis B and C prevalence and obesity-related fatty liver disease, it is expected that the incidence of HCC will also increase in the foreseeable future. This article summarizes the international epidemiology, the risk factors and the pathogenesis of HCC, including the roles of viral hepatitis, toxins, such as alcohol and aflatoxin, and insulin resistance. 展开更多
关键词 Hepatocellular carcinoma EPIDEMIOLOGY Risk factors AETIOLOGY PATHOGENESIS
下载PDF
Role of iron in hepatic fibrosis: One piece in the puzzle 被引量:11
7
作者 Marie A Philippe Richard G Ruddell Grant A Ramm 《World Journal of Gastroenterology》 SCIE CAS CSCD 2007年第35期4746-4754,共9页
Iron is an essential element involved in various biological pathways. When present in excess within the cell, iron can be toxic due to its ability to catalyse the formation of damaging radicals, which promote cellular... Iron is an essential element involved in various biological pathways. When present in excess within the cell, iron can be toxic due to its ability to catalyse the formation of damaging radicals, which promote cellular injury and cell death. Within the liver, iron related oxidative stress can lead to fibrosis and ultimately to cirrhosis. Here we review the role of excessive iron in the pathologies associated with various chronic diseases of the liver. We also describe the molecular mechanism by which iron contributes to the development of hepatic fibrosis. 展开更多
关键词 IRON FIBROSIS Oxidative stress Hepatic stellate cell HAEMOCHROMATOSIS Hepatitis C Non-alcoholic fatty liver disease Alcoholic liver disease
下载PDF
Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma 被引量:38
8
作者 Hai-GangLi De-RongXie +3 位作者 Xi-MingShen Hong-HaoLi HongZeng Yun-JieZeng 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第10期1445-1451,共7页
AIM: To evaluate the relationship of expression of paxillin,syndecan-1 and EMMPRIN proteins with clinicopathological features in hepatocellular carcinoma (HCC).METHODS: Fifty-one patients who underwent HCC resection w... AIM: To evaluate the relationship of expression of paxillin,syndecan-1 and EMMPRIN proteins with clinicopathological features in hepatocellular carcinoma (HCC).METHODS: Fifty-one patients who underwent HCC resection were recruited in the study. Paxillin, syndecan1 and EMMPRIN proteins in HCC tissues were detected with immunohistochemical staining.RESULTS: Of 51 cases of HCC, 23 (45%) exhibited paxillin protein positive expression. Of 42 cases of adjacent nontumor liver tissues, 24 (57%) exhibited positive expression.Positive paxillin protein expression was associated with low differentiation (r= 0.406, P= 0.004), with the presence of portal vein thrombosis (r = 0.325, P = 0.021), with extra-hepatic metastasis (r = 0.346, P = 0.014). Of 51cases of HCC, 28 (55%) exhibited syndecan-1 protein positive expression. Of 42 cases of adjacent non-tumor liver tissues, 23 (55%) exhibited positive expression.Positive snydecan-1 protein expression was associated with well differentiation (r = 0.491, P = 0.001), with no extra-hepatic metastasis (r = 0.346, P = 0.014). Of 51cases of HCC, 28 (55%) exhibited EMMPRIN protein positive expression. Of 42 cases of adjacent non-tumor liver tissues, 21 (50%) exhibited positive expression.Expression of EMMPRIN protein was not associated with serum AFP level, HBsAg status, presence of microsatellite nodule, tumor size, presence of cirrhosis and necrosis,differentiation, presence of portal vein thrombosis, extrahepatic metastasis, disease-free survival and overall survival (P>0.05). Expression of paxillin protein was correlated conversely with the expression of syndecan-1protein in HCC (r = -0.366, P = 0.010).CONCLUSION: Expression of paxillin and syndecan-1proteins in HCC may affect its invasive and metastatic ability of the tumor. There may be a converse correlation between the expression of paxillin and syndecan-1 protein in HCC. Expression of EMMPRIN protein may be detected in HCC, but it may play little role in the invasion and metastasis of HCC. 展开更多
关键词 Hepatocellular carcinoma PAXILLIN SYNDECAN-1 EMMPRIN IMMUNOHISTOCHEMISTRY
下载PDF
Successful management of postoperative recurrence of hepatocellular carcinoma with p53 gene therapy combining transcatheter arterial chemoembolization 被引量:31
9
作者 Yong-SongGuan YuanLiu LongSun XiaoLi QingHe 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第24期3803-3805,共3页
Transcatheter arterial chemoembolization (TACE) has become the standard treatment for unresectable hepatocellular carcinoma (HCC). But this method has some shortages. p53 gene, which was found to be mutant in many hum... Transcatheter arterial chemoembolization (TACE) has become the standard treatment for unresectable hepatocellular carcinoma (HCC). But this method has some shortages. p53 gene, which was found to be mutant in many human tumors, has been proved with broadspectrum anti-tumor effects. We reported a 23-year-old patient with recurrent HCC after irregular hepatectomy. The p53 gene was applied to this patient. We injected percutaneously and infused transcatheterally p53 gene (Gendicine, Shenzhen Sibiono Bentech, China) into his recurrent nodules in liver respectively and 4 d later, the patient received TACE therapy. In the 2 mo follow-up, the patient was in good clinical condition with normal liver function and no recurrence was identified. The case report proposed that recurrent HCC could be successfully treated with p53 gene therapy combining TACE. 展开更多
关键词 Hepatocellular carcinoma Transcatheter arterial chemoembolization p53 gene
下载PDF
Hepatitis B and alcohol affect survival of hepatocellular carcinoma patients 被引量:1
10
作者 Linda L.Wong Whitney M.Limm +1 位作者 Naoky Tsai Richard Severino 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第23期3491-3497,共7页
AIM: In the USA, Hawaii has the highest incidence of hepatocellular carcinoma (HCC) and a diverse population.It is an ideal place to characterize HCC in the context of ethnicity/risk factors.METHODS: A total of 262 ca... AIM: In the USA, Hawaii has the highest incidence of hepatocellular carcinoma (HCC) and a diverse population.It is an ideal place to characterize HCC in the context of ethnicity/risk factors.METHODS: A total of 262 cases of HCC (1992-2003) were retrospectively reviewed for demographics, ethnicity, birthplace, viral hepatitis, alcohol use, diabetes, smoking and risk factors for viral hepatitis such as intravenous drug abuse (IVDA), transfusions, tattoos and vertical transmission. Tumor stage, Child's class, Cancer of the Liver Italian Program (CLIP) score, α-fetoprotein level, treatment and survival were recorded.RESULTS: Gender, age, viral hepatitis, alcohol, IVDA, and diabetes differed significantly in Asians, non-Asians and Pacific Islanders. There were also specific differences within Asian subgroups. Alpha-fetoprotein, smoking, transfusions, stage and resectability did not differ between groups. Asians were more likely to have hepatitis B, while non-Asians were more likely to have hepatitis C. Factors that decreased survival included hepatitis B, alcohol, elevated alpha-fetoprotein, CLIP >2 and increased Child's class. When Asians were combined with Pacific Islanders, median survival (1.52 years vs 3.54 years), 1- and 3-year survival was significantly worse than those for non-Asians. After Cox regression analysis for hepatitis B and alcohol, there was no difference in survival by ethnicity.CONCLUSION: Various ethnicities have different risk factors for HCC. Hepatitis B, alcohol, and α-fetoprotein are more important factors for survival than ethnicity. 展开更多
关键词 Hepatocellular cancer ETHNICITY Hepatitis B
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部